GFAP and nasopharyngeal carcinoma: 36.4% ± 1.7% of cells in the NPC transplant and rehabilitation group expressed the astrocyte marker GFAP compared with 36.2% ± 2.2% in the NPC transplant–alone group (Figure 1, D and G).